Clinical trials: Bladder, Neurogenic
Urinary Incontinence, Overactive Bladder
Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1
The purpose of this study is to provide confirmatory evidence of the safety and efficacy of two Dysport® (AbobotulinumtoxinA) doses (600 units [U] and 800 U), compared to placebo in reducing urinary incontinence (UI) in adult…
- Trial name
- CONTENT1 (NCT02660138)
- Testing
- Botulinum toxin type A
- Where
- 81 sites in United States, Canada and 8 more
- Volunteers
- 227 people
- Sponsor
- Ipsen
Neurogenic Urinary Bladder Disorder, Urinary Bladder, Neurogenic
Efficacy and Tolerability of Propiverine Hydrochloride in Patients With Neurogenic Detrusor Overactivity
The purpose of this clinical study is to compare efficacy and safety of propiverine hydrochloride extended and immediate release formulations in patients suffering from neurogenic detrusor overactivity.
- Conditions
- Neurogenic Urinary Bladder Disorder, Urinary Bladder, Neurogenic, Bladder Disorder, Neurogenic, Urinary Bladder Disorder, Neurogenic
- Trial name
- NCT01530620
- Testing
- Propiverine hydrochloride ER (extended release), Propiverine hydrochloride IR (immediate release)
- Where
- 3 sites in Austria, Germany and 1 more
- Volunteers
- 66 people
- Sponsor
- APOGEPHA Arzneimittel GmbH
Urinary Bladder Neurogenic
Pharmacokinetics and Safety Study With Alfuzosin in Children and Adolescents With Elevated Detrusor Leak Point Pressure of Neuropathic Etiology
The primary objective is to investigate the pharmacokinetics (PK) of 2 doses of alfuzosin (given as a solution or tablets depending on age) in children and adolescents 2 to 16 years of age with elevated detrusor Leak Point…
- Trial name
- ALFACHIP (NCT00629720)
- Testing
- alfuzosin (SL770499)
- Where
- 2 sites in United States, Serbia
- Volunteers
- 29 people
- Sponsor
- Sanofi
Neurogenic Urinary Bladder, Neurogenic Bladder Disorder
Safety and Efficacy of SAF312 in Patients With Neurogenic Detrusor Overactivity Due to Spinal Cord Lesions
This study will assess the safety, tolerability and efficacy of SAF312 in patients with overactive bladder disease due to spinal cord lesions.
- Conditions
- Neurogenic Urinary Bladder, Neurogenic Bladder Disorder, Neurogenic Dysfunction of the Urinary Bladder, Neurogenic Bladder, Uninhibited
- Trial name
- NCT01598103
- Testing
- SAF312
- Where
- 3 sites in Germany, Netherlands and 1 more
- Volunteers
- 9 people
- Sponsor
- Novartis Pharmaceuticals
Overactive Bladder, Neurogenic Detrusor Overactivity
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron Oral Suspension in Pediatric Subjects From 3 to Less Than 12 Years of Age With Neurogenic Detrusor Overactivity (NDO) or Overactive Bladder (OAB)
The purpose of the study is to evaluate the pharmacokinetics (PK) of mirabegron oral suspension after single dose administration in children with neurogenic detrusor overactivity (NDO) or overactive bladder (OAB).
- Trial name
- NCT02526979
- Testing
- mirabegron
- Where
- 3 sites in Denmark, Poland
- Volunteers
- 9 people
- Sponsor
- Astellas Pharma Europe B.V.
Urinary Incontinence, Multiple Sclerosis
Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)
This study will evaluate the safety and efficacy of OnabotulinumtoxinA (BOTOX®) for the treatment of urinary incontinence due to NDO in non-catheterizing patients with MS.
- Conditions
- Urinary Incontinence, Multiple Sclerosis, Neurogenic Bladder
- Trial name
- NCT01600716
- Testing
- OnabotulinumtoxinA
- Where
- 10 sites in United States, Belgium and 6 more
- Volunteers
- 144 people
- Sponsor
- Allergan
Overactive Bladder
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder
The purpose of this study is to assess the safety and effectiveness of botulinum toxin type A in treating overactive bladder in spinal cord injury or multiple sclerosis patients.
- Trial name
- NCT00311376
- Testing
- botulinum toxin Type A (200U), botulinum toxin Type A (300U)
- Where
- 14 sites in United States, Australia and 12 more
- Volunteers
- 416 people
- Sponsor
- Allergan
Neurogenic Bladder
Study of Autologous Neo-Bladder Construct in Subjects With Neurogenic Bladder Following Spinal Cord Injury
Subjects with neurogenic bladder secondary to spinal cord injury that is refractory to medical treatment and requires augmentation cystoplasty will be enrolled.
- Trial name
- NCT00512148
- Testing
- Autologous neobladder construct
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Tengion
Urinary Retention, Neurogenic Bladder
Connected Catheter (C2P) Study for Bladder Management
The objective of this study is to evaluate the safety and essential performance of the C2P System in males with neurogenic lower urinary tract dysfunction (NLUTD), both in an acute clinical setting and an extended period of home…
- Trial name
- NCT03626324
- Testing
- C2P
- Where
- 8 sites in United States
- Volunteers
- 27 people
- Sponsor
- Spinal Singularity
Urinary Incontinence, Urge Incontinence
UCon Treatment of Overactive Bladder (OAB) in Males
UCon is a medical device for treatment of the symptoms of OAB and fecal incontinence (FI). It electrically stimulates the DGN through the skin to obtain modulated behaviour of the bladder musculature e.g., suppress undesired…
- Conditions
- Urinary Incontinence, Urge Incontinence, Nocturia, Urinary Frequency More Than Once at Night
- Trial name
- NCT05874375
- Testing
- Urge stimulation, Time limited stimulation
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- InnoCon Medical
Detrusor Hyperreflexia
A Study Evaluating Oxybutynin in Patients With Neurogenic Overactive Bladder Associated With a Neurological Condition
This study will evaluate the efficacy and safety of an anticholinergic drug treatment administered by transdermal patch to treat overactive bladder in adults who have spinal cord injury.
- Trial name
- NCT00224029
- Testing
- Oxybutynin transdermal system
- Where
- 6 sites in United States
- Volunteers
- 24 people
- Sponsor
- Watson Pharmaceuticals
Urinary Incontinence, Overactive Bladder
A Safety and Efficacy Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in Korean Patients
This is a safety and efficacy study of BOTOX® (Botulinum Toxin Type A) in the Treatment of Adult Korean Patients with Urinary Incontinence due to Neurogenic Detrusor Overactivity or Overactive Bladder.
- Trial name
- NCT02601287
- Testing
- Botulinum Toxin Type A
- Where
- 5 sites in South Korea
- Volunteers
- 168 people
- Sponsor
- Allergan
Urinary Bladder, Neurogenic
Open-label Long-term Extension Study of Fesoterodine in Japanese Subjects With Neurogenic Detrusor Overactivity.
The purpose of this study is to investigate the safety and tolerability of fesoterodine following once daily long-term treatment in Japanese pediatric neurogenic detrusor overactivity (NDO) subjects.
- Trial name
- NCT02501928
- Testing
- Fesoterodine PR 4 mg, Fesoterodine PR 8 mg, Fesoterodine BIC 2 mg
- Where
- 7 sites in Japan
- Volunteers
- 12 people
- Sponsor
- Pfizer
Neurogenic Urinary Bladder
Alfuzosin Treatment in Children and Adolescents With Neurogenic Urinary Bladder Dysfunction
The primary objective of the study was to evaluate the efficacy of Alfuzosin in comparison to Placebo on the detrusor Leak Point Pressure (LPP) in children and adolescents 2-16 years of age with elevated detrusor LPP of…
- Trial name
- ALFACHIN (NCT00549939)
- Testing
- Alfuzosin
- Where
- 18 sites in United States, Bulgaria and 16 more
- Volunteers
- 172 people
- Sponsor
- Sanofi
Urinary Incontinence, Urinary Obstruction
NXT Post-Market Clinical Follow-up
NXT Urodynamics System Post-Market Clinical Follow-up Clinical Investigation to Confirm Ongoing Safety and Performance in Urodynamic Patient Sub-Populations
- Conditions
- Urinary Incontinence, Urinary Obstruction, Urinary Bladder, Overactive, Urinary Bladder, Neurogenic
- Trial name
- NCT06336304
- Testing
- Urodynamic procedure
- Where
- 5 sites in United States
- Volunteers
- 163 people
- Sponsor
- Laborie Medical Technologies Inc.
Neurogenic Detrusor Overactivity
A Two-week Open-label Pharmacodynamic and Pharmacokinetic Study of Multiple Doses of a Darifenacin Liquid Oral Suspension in Children (2 - 15 Years) With Neurogenic Detrusor Overactivity
This study will evaluate the pharmacodynamics and pharmacokinetics of darifenacin liquid oral suspension in children, ages 2-15 years, with neurogenic detrusor overactivity.
- Trial name
- NCT00712322
- Testing
- Darifenacin
- Where
- 12 sites in United States, Colombia
- Volunteers
- 35 people
- Sponsor
- Warner Chilcott
Urinary Bladder, Neurogenic
Connected Catheter Clinical Feasibility Study( CFS)
The objective of this study is to evaluate the safety and essential performance of the Connected Catheter System in males with neurogenic lower urinary tract dysfunction (NLUTD), both in an acute clinical setting, and during and…
- Trial name
- NCT03405285
- Testing
- Connected Catheter
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Spinal Singularity
Neurogenic Bladder Dysfunction Nos
Quality of Life Intermittent Catheter Study
The purpose of this study is to compare compact intermittent catheters with standard coated intermittent catheters with regard to quality of life, using the Intermittent Self-Catheterisation Quality of life Measure.
- Trial name
- NCT01523743
- Testing
- SpeediCath Compact, Standard care
- Where
- 11 sites in Denmark, France and 3 more
- Volunteers
- 125 people
- Sponsor
- Coloplast A/S
Urinary Incontinence, Overactive Bladder
A Safety and Efficacy Study of BOTOX® (Botulinum Toxin Type A) in Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in India
This is a Post-Marketing Surveillance study in India to evaluate safety and efficacy of BOTOX® (Botulinum Toxin Type A) in the treatment of patients with urinary incontinence due to neurogenic detrusor overactivity or overactive…
- Trial name
- NCT02590250
- Testing
- botulinum toxin Type A
- Where
- 12 sites in India
- Volunteers
- 250 people
- Sponsor
- Allergan
Urinary Bladder, Overactive
Efficacy and Safety Study of GSK1358820 in Japanese Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity
This study will evaluate the efficacy and safety of GSK1358820 in Japanese patients with neurogenic detrusor overactivity (NDO) with urinary incontinence, whose symptoms have not been adequately managed with medications for…
- Trial name
- NCT02849418
- Testing
- GSK1358820
- Where
- 9 sites in Japan
- Volunteers
- 21 people
- Sponsor
- GlaxoSmithKline